Given the implication of the JAK-STAT pathway in the production of proinflammatory cytokines, the repurposing of several JAK inhibitors has been proposed to ameliorate COVID-19 symptomatology (reviewed elsewhere in References [90,91,92]). The gene discussed is SOAT1; the disease is COVID-19.